HS-20093

Phase 3Small molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-20093 is one of 336 small molecule programs targeting Esophageal Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

335

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal CarcinomaRecruiting

OsteosarcomaRecruiting

Metastatic Colorectal CancerRecruiting

Non-Small Cell Lung CancerNot yet recruiting

Pancreatic CancerNot yet recruiting

Prostate CancerRecruiting

Head and Neck Squamous Cell CarcinomaRecruiting

Small Cell Lung CancerNot yet recruiting

Patients With Advanced Solid TumorsUnknown status

Soft Tissue SarcomaNot yet recruiting

Esophageal CarcinomaPhase 2

Recruiting

OsteosarcomaPhase 2

Recruiting

Metastatic Colorectal CancerPhase 1

Recruiting

Non-Small Cell Lung CancerPhase 3

Not yet recruiting

Pancreatic CancerPreclinical

Not yet recruiting

Prostate CancerPhase 2

Recruiting

Head and Neck Squamous Cell CarcinomaPhase 2

Recruiting

Small Cell Lung CancerPhase 3

Not yet recruiting

Patients With Advanced Solid TumorsPhase 1

Unknown status

Soft Tissue SarcomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

9 2

DATROWAY

Daiichi Sankyo

Phase 3

5 3

Navmi

SSummit Therapeutics

Phase 3

7 4

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Metastatic Colorectal Cancer

NCT06825624

Phase 2Recruiting

Esophageal Carcinoma

NCT06112704

Q4 2027

Phase 2Recruiting

Head and Neck Squamous Cell Carcinoma

NCT06007729

Phase 2Recruiting

Osteosarcoma

NCT05830123

Q2 2028

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT06332170

Q4 2028

Phase 1Recruiting

Prostate Cancer

NCT07115446

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors4 trials

Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT07186452·18 enrolled

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06332170·610 enrolled

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT06963502·762 enrolled

Show 1 more trial

ARTEMIS-001: Phase 1 Study of the HS-20093 in Patients With Advanced Solid Tumors

Unknown status·SShanghai Hansoh Biomedical Co., Ltd·Phase 1·NCT05276609·177 enrolled

Small Cell Lung Cancer3 trials

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

Not yet recruiting·HHansoh BioMedical R&D Company·Phase 3·NCT06526624·406 enrolled

ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer

Withdrawn·HHansoh BioMedical R&D Company·Phase 2·NCT06052423

ARTEMIS-008：A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy

Completed·HHansoh BioMedical R&D Company·Phase 3·NCT06498479·461 enrolled

Prostate Cancer2 trials

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 2·NCT06001255·120 enrolled

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT07115446·63 enrolled

Osteosarcoma2 trials

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

Recruiting·HHansoh BioMedical R&D Company·Phase 2·NCT05830123·170 enrolled

A Randomized, Controlled, Open-label, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of HS-20093 for Injection Versus Gemcitabine in Combination With Docetaxel in the Treatment of Osteosarcoma After Previous Second-line Treatment Failure (ARTEMIS-011)

Completed·HHansoh BioMedical R&D Company·Phase 3·NCT06935409·122 enrolled

Non-Small Cell Lung Cancer2 trials

A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations

Not yet recruiting·HHansoh BioMedical R&D Company·Phase 3·NCT07464327·450 enrolled

A Phase I Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HS-20093 Combination Therapy in Subjects With Advanced Non-Small Cell Lung Cancer

Not yet recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT07899086·102 enrolled

5 more indications

Head and Neck Squamous Cell Carcinoma1 trial

ARTEMIS-006: HS-20093 in Patients With Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 2·NCT06007729·170 enrolled

Metastatic Colorectal Cancer1 trial

ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06825624·560 enrolled

Soft Tissue Sarcoma1 trial

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Not yet recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06699576·448 enrolled

Esophageal Carcinoma1 trial

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 2·NCT06112704·220 enrolled

Pancreatic Cancer1 trial

A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

Not yet recruiting·ZZhejiang University·Preclinical·NCT07736612·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for HS-20093. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-20093 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-20093. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-20093

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors4 trials

Small Cell Lung Cancer3 trials

Prostate Cancer2 trials

Osteosarcoma2 trials

Non-Small Cell Lung Cancer2 trials

Head and Neck Squamous Cell Carcinoma1 trial

Metastatic Colorectal Cancer1 trial

Soft Tissue Sarcoma1 trial

Esophageal Carcinoma1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News